Table 1

ASAS20, ASAS40, BASDAI and Berlin score data at week 94*

Subject NoASAS20 response (week 6/week 94)ASAS40 response (week 6/week 94)BASDAI50% response (% change from core study BL in BASDAI score)BASDAI total score at week 94Berlin score decrease (absolute change from core study BL)
1Yes/YesNo/YesYes (−71.4%)1.3Yes (−4)
2Yes/NoYes/NoNo (−34.2%)4.3No (0)
3Yes/YesYes/YesYes (−52.1%)3.0Yes (−16)
4Yes/NoNo/NoNo (−46.5%)2.9Yes (−18)
5Yes/YesYes/NoNo (−43.3%)4.3No (0)
6Yes/YesNo/YesNo (−37.9%)4.4Yes (−1)
7Yes/YesYes/YesYes (−52.3%)4.0Yes (−7)
8Yes/YesYes/YesNo (−44.6%)3.1No (0)
9No/NoNo/NoNo (−8.1%)6.0No (+1)
10No/NoNo/NoNo (−16.5%)6.2No (+1)
11†Yes/NoYes/NoNo (−21.9%)4.3Yes (−10)
12†No/YesNo/NoYes (−50.2%)3.6Yes (−1)
13†No/YesNo/YesYes (−52.5%)2.7Yes (−12)
  • *The week 94/end-of-study visit occurred a mean of 94 weeks (range 85–106 weeks) after the core study baseline MRI.

  • †Subjects 11–13 were placebo/secukinumab subjects (subjects who received placebo during the core study and secukinumab 3 mg/kg IV during this study); subjects 1–10 received secukinumab 2×10 mg/kg IV during the core study and secukinumab 3 mg/kg IV during this study.

  • ASAS20/40, Assessment of SpondyloArthritis international Society 20%/40% response; BASDAI50%, Bath Ankylosing Spondylitis Disease Activity Index 50% response; BL, baseline.